Phenotype standardisation of angioedema in the head and neck region caused by agents acting on the angiotensin system

Mia Wadelius; Sara E. Marshall; Gunilla Islander; Leif Nordang; Malgorzata Karawajczyk; Qun-Ying Yue; Ingrid Terreehorst; Ekaterina V. Baranova; Svante Hugosson; Karin Sköldefors; Munir Pirmohamed; Anke-Hilse  Maitland van der Zee; Ana Alfirevic; Pär Hallberg; Colin N. A.  Palmer

doi:10.1038/clpt.2014.138

Phenotype standardisation of angioedema in the head and neck region caused by agents acting on the angiotensin system

Mia Wadelius (Lead / Corresponding author), Sara E. Marshall, Gunilla Islander, Leif Nordang, Malgorzata Karawajczyk, Qun-Ying Yue, Ingrid Terreehorst, Ekaterina V. Baranova, Svante Hugosson, Karin Sköldefors, Munir Pirmohamed, Anke-Hilse Maitland van der Zee, Ana Alfirevic, Pär Hallberg, Colin N. A. Palmer

Research output: Contribution to journal › Review article › peer-review

17 Citations (Scopus)

Abstract

Angioedema is a potentially life-threatening adverse reaction to angiotensin converting enzyme inhibitors and angiotensin receptor blockers. To study the genetic etiology of this rare adverse event, international consortia and multicentre recruitment of patients are needed. To reduce patient heterogeneity, we have standardised the phenotype. In brief, it comprises swelling in the head and neck region that first occurs during treatment. It should not coincide with urticaria or have another likely cause such as hereditary angioedema.

Original language	English
Pages (from-to)	477-481
Journal	Clinical Pharmacology & Therapeutics
Volume	96
Issue number	4
Early online date	24 Jun 2014
DOIs	https://doi.org/10.1038/clpt.2014.138
Publication status	Published - Oct 2014

Keywords

Drug-Related Side Effects and Adverse Reactions
Angioedema
Renin-Angiotensin System
Angiotensin-Converting Enzyme Inhibitors
Angiotensin Receptor Antagonists
Phenotype
Reference Standards

Access to Document

10.1038/clpt.2014.138

PREDICTION-ADR: Personalisation of tREatment In Cardiovascular Disease Through Next Generation Sequencing - Adverse Drug Reactions (Joint with University of Uppsala, University of Liverpool and University of Utrecht)
Palmer, C. (Investigator)
COMMISSION OF THE EUROPEAN COMMUNITIES
1/09/13 → 28/02/17
Project: Research

Palmer, Colin
- Population Health and Genomics - Professor (Teaching and Research) of Pharmacogenomics
Person: Academic

Cite this

Wadelius, M., Marshall, S. E., Islander, G., Nordang, L., Karawajczyk, M., Yue, Q.-Y., Terreehorst, I., Baranova, E. V., Hugosson, S., Sköldefors, K., Pirmohamed, M., Maitland van der Zee, A.-H., Alfirevic, A., Hallberg, P., & Palmer, C. N. A. (2014). Phenotype standardisation of angioedema in the head and neck region caused by agents acting on the angiotensin system. Clinical Pharmacology & Therapeutics, 96(4), 477-481. https://doi.org/10.1038/clpt.2014.138

@article{f5753b0b132045bbb920943cacc62d3e,

title = "Phenotype standardisation of angioedema in the head and neck region caused by agents acting on the angiotensin system",

abstract = "Angioedema is a potentially life-threatening adverse reaction to angiotensin converting enzyme inhibitors and angiotensin receptor blockers. To study the genetic etiology of this rare adverse event, international consortia and multicentre recruitment of patients are needed. To reduce patient heterogeneity, we have standardised the phenotype. In brief, it comprises swelling in the head and neck region that first occurs during treatment. It should not coincide with urticaria or have another likely cause such as hereditary angioedema.",

keywords = "Drug-Related Side Effects and Adverse Reactions, Angioedema, Renin-Angiotensin System, Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Antagonists, Phenotype, Reference Standards",

author = "Mia Wadelius and Marshall, {Sara E.} and Gunilla Islander and Leif Nordang and Malgorzata Karawajczyk and Qun-Ying Yue and Ingrid Terreehorst and Baranova, {Ekaterina V.} and Svante Hugosson and Karin Sk{\"o}ldefors and Munir Pirmohamed and {Maitland van der Zee}, Anke-Hilse and Ana Alfirevic and P{\"a}r Hallberg and Palmer, {Colin N. A.}",

year = "2014",

month = oct,

doi = "10.1038/clpt.2014.138",

language = "English",

volume = "96",

pages = "477--481",

journal = "Clinical Pharmacology & Therapeutics",

issn = "0009-9236",

publisher = "Wiley",

number = "4",

}

Wadelius, M, Marshall, SE, Islander, G, Nordang, L, Karawajczyk, M, Yue, Q-Y, Terreehorst, I, Baranova, EV, Hugosson, S, Sköldefors, K, Pirmohamed, M, Maitland van der Zee, A-H, Alfirevic, A, Hallberg, P & Palmer, CNA 2014, 'Phenotype standardisation of angioedema in the head and neck region caused by agents acting on the angiotensin system', Clinical Pharmacology & Therapeutics, vol. 96, no. 4, pp. 477-481. https://doi.org/10.1038/clpt.2014.138

TY - JOUR

T1 - Phenotype standardisation of angioedema in the head and neck region caused by agents acting on the angiotensin system

AU - Wadelius, Mia

AU - Marshall, Sara E.

AU - Islander, Gunilla

AU - Nordang, Leif

AU - Karawajczyk, Malgorzata

AU - Yue, Qun-Ying

AU - Terreehorst, Ingrid

AU - Baranova, Ekaterina V.

AU - Hugosson, Svante

AU - Sköldefors, Karin

AU - Pirmohamed, Munir

AU - Maitland van der Zee, Anke-Hilse

AU - Alfirevic, Ana

AU - Hallberg, Pär

AU - Palmer, Colin N. A.

PY - 2014/10

Y1 - 2014/10

N2 - Angioedema is a potentially life-threatening adverse reaction to angiotensin converting enzyme inhibitors and angiotensin receptor blockers. To study the genetic etiology of this rare adverse event, international consortia and multicentre recruitment of patients are needed. To reduce patient heterogeneity, we have standardised the phenotype. In brief, it comprises swelling in the head and neck region that first occurs during treatment. It should not coincide with urticaria or have another likely cause such as hereditary angioedema.

AB - Angioedema is a potentially life-threatening adverse reaction to angiotensin converting enzyme inhibitors and angiotensin receptor blockers. To study the genetic etiology of this rare adverse event, international consortia and multicentre recruitment of patients are needed. To reduce patient heterogeneity, we have standardised the phenotype. In brief, it comprises swelling in the head and neck region that first occurs during treatment. It should not coincide with urticaria or have another likely cause such as hereditary angioedema.

KW - Drug-Related Side Effects and Adverse Reactions

KW - Angioedema

KW - Renin-Angiotensin System

KW - Angiotensin-Converting Enzyme Inhibitors

KW - Angiotensin Receptor Antagonists

KW - Phenotype

KW - Reference Standards

U2 - 10.1038/clpt.2014.138

DO - 10.1038/clpt.2014.138

M3 - Review article

C2 - 24960520

SN - 0009-9236

VL - 96

SP - 477

EP - 481

JO - Clinical Pharmacology & Therapeutics

JF - Clinical Pharmacology & Therapeutics

IS - 4

ER -

Phenotype standardisation of angioedema in the head and neck region caused by agents acting on the angiotensin system

Abstract

Keywords

Access to Document

Fingerprint

Projects

PREDICTION-ADR: Personalisation of tREatment In Cardiovascular Disease Through Next Generation Sequencing - Adverse Drug Reactions (Joint with University of Uppsala, University of Liverpool and University of Utrecht)

Profiles

Palmer, Colin

Cite this